1. A compound having Formula 1:



Formula 1

,

a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein

R_1 is hydrogen; cyclo-(C_3-C_6 alkyl)-methyl; straight or branched chain C_1-C_7 alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; sulfonamide; C_1-C_6 alkoxy; (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy; (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl; mono- or di(C_1-C_6 alkyl)amino, mono- or di(C_1-C_6 alkyl)amino(C_1-C_6 alkyl); or phenyl or heteroaryl ring which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, sulfonamide, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, -S(C_1-C_6 alkyl), mono- or di(C_1-C_6 alkyl)amino, mono- or di(C_1-C_6 alkyl)amino(C_1-C_6 alkyl), or carboxylic acid or ester;

R_2 is straight or branched chain C_1-C_7 alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; cyclo-(C_3-C_6 alkyl)-methyl; C_1-C_6 alkoxy; (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy; (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl; phenyl or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl,

mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, mono- or di(C_1-C_6 alkyl)amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; and wherein R_2 can form a 3-7 heteroalkyl or alkyl with R_{10}, R_{11}, or R_{12};

R_3 is hydrogen; carboxylic acid or ester; straight or branched chain C_1-C_6 alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; phenyl or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, mono- or di(C_1-C_6 alkyl)amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester;

R_4 is hydrogen; straight or branched chain C_1-C_6 alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl; phenyl or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-

C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, mono- or di(C_1-C_6 alkyl)amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; or form a 3-7 member heteroalkyl or alkyl with Z_1 or R_1;

X is N or CH

Z_1 is



wherein

each occurrence of R_5 and R_6 is independently hydrogen straight or branched chain C_1-C_6 alkyl, sulfonamide, or halogen;

m is 0, 1, or 2; and

R_7 is hydrogen; straight or branched chain C_1-C_6 alkyl; phenyl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino,

amino(C_1-C_6 alkyl) , -S(C_1-C_6 alkyl), or carboxylic acid or ester; or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl) , -S(C_1-C_6 alkyl), or carboxylic acid or ester; and

Z_2 is



wherein

each occurrence of R_8 and R_9 is independently straight or branched chain C_1-C_6 alkyl, sulfonamide, or halogen;

n is 0, 1, or 2; and

R_{10}-R_{13} are each independently hydrogen; straight or branched chain C_1-C_6 alkyl; phenyl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; or heteroaryl which may be unsubstituted, mono-, di- or

trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl) , -S(C_1-C_6 alkyl), or carboxylic acid or ester;

and wherein, when R_3 is hydrogen and R_4 is hydrogen, or when R_3 and R_1 are hydrogen and Z_1 is  wherein m is 0, the combination of Z_2-R_2 is not hydrogen, hydroxy, halogen, hydroxyamide, amino, hydroxyalkyl, aminoalkylamide, alkylamide, arylamide or alkoxy, or

wherein when R_3 is hydrogen, R_4 and Z_1, or R_4 and R_1 do not form a morpholino, piperazinyl, or 1,4-diazepanyl group when the combination of Z_2-R_2 is hydrogen, hydroxy, halogen, hydroxyamide, amino, hydroxyalkyl, aminoalkylamide, alkylamide, arylamide or alkoxy.

2. A compound having Formula 2:



Formula 2

,

a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixtures thereof, wherein

R_1 is phenyl or heteroaryl ring which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, sulfonamide, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, -S(C_1-C_6 alkyl), mono- or di(C_1-C_6 alkyl)amino, mono- or di(C_1-C_6 alkyl)amino(C_1-C_6 alkyl), or carboxylic acid or ester;

R_2 is phenyl or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, mono- or di(C_1-C_6

alkyl)amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; and wherein R_2 can form a 3-7 heteroalkyl or alkyl with R_{10}, R_{11}, or R_{12};

R_3 is hydrogen; or carboxylic acid or ester;

R_4 is hydrogen; straight or branched chain C_1-C_6 alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; or (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl;

X is N or CH

Z_1 is



wherein

each occurrence of R_5 and R_6 is independently hydrogen straight or branched chain C_1-C_6 alkyl, sulfonamide, or halogen;

m is 0, 1, or 2; and

Z_2 is



wherein

R_{10}-R_{13} are each independently hydrogen; straight or branched chain C_1-C_6 alkyl; phenyl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl) , -S(C_1-C_6 alkyl), or carboxylic acid or ester;

and wherein, when R_3 is hydrogen and R_4 is hydrogen, or when R_3 and R_1 are hydrogen and Z_1 is  wherein m is 0, the combination of Z_2-R_2 is not hydrogen, hydroxy, halogen, hydroxyamide, amino, hydroxyalkyl, aminoalkylamide, alkylamide, arylamide or alkoxy, or

wherein when R_3 is hydrogen, R_4 and Z_1, or R_4 and R_1 do not form a morpholino, piperazinyl, or 1,4-diazepanyl group when the combination of Z_2-R_2 is hydrogen, hydroxy, halogen, hydroxyamide, amino, hydroxyalkyl, aminoalkylamide, alkylamide, arylamide or alkoxy.

3. A compound having Formula 3:



Formula 3

,

a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixtures thereof, wherein

R_1 is hydrogen; cyclo-(C_3-C_6 alkyl)-methyl; straight or branched chain C_1-C_7 alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; sulfonamide; C_1-C_6 alkoxy; (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy; (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl; mono- or di(C_1-C_6 alkyl)amino, mono- or di(C_1-C_6 alkyl)amino(C_1-C_6 alkyl); or phenyl or heteroaryl ring which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, sulfonamide, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, -S(C_1-C_6 alkyl), mono- or di(C_1-C_6 alkyl)amino, mono- or di(C_1-C_6 alkyl)amino(C_1-C_6 alkyl), or carboxylic acid or ester;

R_2 is straight or branched chain C_1-C_7 alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; cyclo-(C_3-C_6 alkyl)-methyl; C_1-C_6 alkoxy; (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy; (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl; phenyl or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6

perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, mono- or di(C_1-C_6 alkyl)amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; and wherein R_2 can form a 3-7 heteroalkyl or alkyl with R_{12};

R_3 is hydrogen; carboxylic acid or ester; straight or branched chain C_1-C_6 alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; phenyl or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, mono- or di(C_1-C_6 alkyl)amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester;

R_4 is hydrogen; straight or branched chain C_1-C_6 alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl; phenyl or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-

C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, mono- or di(C_1-C_6 alkyl)amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; or form a 3-7 member heteroalkyl or alkyl with Z_1 or R_1;

X is N or CH

Z_1 is



wherein

each occurrence of R_5 and R_6 is independently hydrogen straight or branched chain C_1-C_6 alkyl, sulfonamide, or halogen;

m is 0, 1, or 2; and

R_7 is hydrogen; straight or branched chain C_1-C_6 alkyl; phenyl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy,

(C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl) , -S(C_1-C_6 alkyl), or carboxylic acid or ester; or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl) , -S(C_1-C_6 alkyl), or carboxylic acid or ester; and

wherein R_{12} and R_{13} are each independently hydrogen; straight or branched chain C_1-C_6 alkyl; phenyl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl), -S(C_1-C_6 alkyl), or carboxylic acid or ester; or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 perfluoroalkyl, C_1-C_6 perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono- or di(C_1-C_6 alkyl)amino, amino(C_1-C_6 alkyl) , -S(C_1-C_6 alkyl), or carboxylic acid or ester.

4. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is1-(4-{8-[(3-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(2-chloro-phenyl)-urea.

5. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(4-{8-[(3-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-chloro-phenyl)-urea.

6. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(4-{8-[(3-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(2-methoxy-phenyl)-urea.

7. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(4-{8-[(3-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-phenyl)-urea.

8. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-phenyl)-urea.

9. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(4-{8-[(3-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-trifluoromethyl-phenyl)-urea.

10. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(4-{8-[(3-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-trifluoromethoxy-phenyl)-urea.

11. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(2-methylsulfanyl-phenyl)-urea.

12. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[Methyl-(4-methyl-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(2-methylsulfanyl-phenyl)-urea.

13. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(4-Chloro-phenyl)-3-(3-{8-[methyl-(4-methyl-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.

14. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[Methyl-(4-methyl-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-o-tolyl-urea.

15. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(4-Chloro-phenyl)-3-{3-[8-(3,4-dihydro-1H-isoquinolin-2-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

16. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-{3-[8-(3,4-Dihydro-1H-isoquinolin-2-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(2-methylsulfanyl-phenyl)-urea.

17. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-{3-[8-(3,4-Dihydro-1H-isoquinolin-2-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-o-tolyl-urea.

18. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-{3-[8-(3,4-Dihydro-1H-isoquinolin-2-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(2-methoxy-phenyl)-urea.

19. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 8-[(4-Chloro-benzyl)-methyl-amino]-6-{3-[3-(2-trifluoromethyl-phenyl)-ureido]-phenyl}-imidazo[1,2-a]pyrazine-3-carboxylic acid ethyl ester.

20. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 8-[(4-Chloro-benzyl)-methyl-amino]-6-[3-(3-o-tolyl-ureido)-phenyl]-imidazo[1,2-a]pyrazine-3-carboxylic acid ethyl ester.

21. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 8-[(4-Chloro-benzyl)-methyl-amino]-6-{3-[3-(4-chloro-phenyl)-ureido]-phenyl}-imidazo[1,2-a]pyrazine-3-carboxylic acid ethyl ester.

22. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-(3-{8-[methyl-(4-methyl-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.

23. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-chloro-4-fluoro-phenyl)-urea.

24. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-benzyl)-3-(4-chloro-phenyl)-urea.

25. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-benzyl)-3-(3-chloro-4-fluoro-phenyl)-urea.

26. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-ethyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-o-tolyl-urea.

27. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-ethyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-phenyl)-urea.

28. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-ethyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-chloro-4-fluoro-phenyl)-urea.

29. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-propyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-o-tolyl-urea.

30. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-propyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-chloro-4-fluoro-phenyl)-urea.

31. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[Butyl-(4-chloro-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-o-tolyl-urea.

32. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-propyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-phenyl)-urea.

33. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-propyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-trifluoromethyl-phenyl)-urea.

34. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[Butyl-(4-chloro-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-phenyl)-urea.

35. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[Butyl-(4-chloro-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-trifluoromethyl-phenyl)-urea.

36. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[Butyl-(4-chloro-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-chloro-4-fluoro-phenyl)-urea.

37. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-trifluoromethyl-phenyl)-urea.

38. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-o-tolyl-urea.

39. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-{3-[8-(Benzyl-methyl-amino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(4-chloro-phenyl)-urea.

40. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-trifluoromethoxy-phenyl)-urea.

41. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(5-fluoro-2-trifluoromethyl-phenyl)-urea.

42. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3,5-dichloro-phenyl)-urea.

43. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3,4-dichloro-phenyl)-urea.

44. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(2-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-phenyl)-urea.

45. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-{3-[8-(Methyl-pyridin-4-ylmethyl-amino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-trifluoromethyl-phenyl)-urea.

46. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(4-Chloro-benzyl)-3-(3-{8-[(4-chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.

47. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-(2-methoxy-ethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-phenyl)-urea.

48. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-(2-methoxy-ethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-trifluoromethyl-phenyl)-urea.

49. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-(2-methoxy-ethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-3-fluoro-phenyl)-urea.

50. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-(2-methoxy-ethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-urea.

51. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is (2-Methoxy-benzyl)-{6-[3-(4-methoxy-benzylamino)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine.

52. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-{4-[8-(2-Methoxy-benzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-phenyl-urea.

53. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(2-Chloro-phenyl)-3-{4-[8-(2-methoxy-benzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

54. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-{4-[8-(2-Methoxy-benzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(2-methoxy-phenyl)-urea.

55. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-{4-[8-(2-Methoxy-benzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-methoxy-phenyl)-urea.

56. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is N-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzenesulfonamide.

57. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is N-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzamide.

58. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 4-Chloro-N-(3-{8-[(4-chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzamide.

59. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 2-Chloro-N-(3-{8-[(4-chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzamide.

60. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is (4-{8-[(3-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-piperidin-1-yl-methanone.

61. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is (4-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-piperidin-1-yl-methanone.

62. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 4-{6-[4-(Piperidine-1-carbonyl)-phenyl]-imidazo[1,2-a]pyrazin-8-ylamino}-benzoic acid ethyl ester.

63. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 4-(6-{3-[3-(4-Chloro-phenyl)-ureido]-phenyl}-imidazo[1,2-a]pyrazin-8-ylamino)-benzoic acid ethyl ester.

64. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 4-(6-{3-[3-(2-Methylsulfanyl-phenyl)-ureido]-phenyl}-imidazo[1,2-a]pyrazin-8-ylamino)-benzoic acid ethyl ester.

65. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(2-methylsulfanyl-phenyl)-urea.

66. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is {4-[8-(4-Chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-piperidin-1-yl-methanone.

67. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 3-Methoxy-N-{3-[8-(2-methoxy-benzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-benzamide.

68. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 2-Methoxy-N-{3-[8-(2-methoxy-benzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-benzamide.

69. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-urea.

70. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(4-Chloro-phenyl)-3-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-urea.

71. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-[3-(8-Phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-3-(3-trifluoromethyl-phenyl)-urea.

72. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(2-Chloro-5-trifluoromethyl-phenyl)-3-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-urea.

73. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(4-Chloro-phenyl)-3-{3-[8-(4-chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

74. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-{3-[8-(4-Chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-trifluoromethyl-phenyl)-urea.

75. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-{3-[8-(3-chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

76. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(4-Chloro-phenyl)-3-{3-[8-(3-chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

77. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-{3-[8-(3-Chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-trifluoromethyl-phenyl)-urea.

78. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-{3-[8-(2-chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

79. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-[3-(8-Phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-3-(4-trifluoromethyl-phenyl)-urea.

80. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-(3-{8-[(pyridin-2-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.

81. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(4-Chloro-phenyl)-3-(3-{8-[(pyridin-3-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.

82. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-(3-{8-[(pyridin-3-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.

83. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(4-Chloro-phenyl)-3-(3-{8-[(pyridin-4-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.

84. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(Pyridin-4-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-trifluoromethyl-phenyl)-urea.

85. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-(3-{8-[(pyridin-4-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.

86. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-{3-[8-(Pyridin-4-ylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-trifluoromethyl-phenyl)-urea.

87. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-{3-[8-(pyridin-4-ylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

88. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(4-Chloro-phenyl)-3-(3-{8-[(pyridin-2-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.

89. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-{8-[(Pyridin-2-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-trifluoromethyl-phenyl)-urea.

90. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(2-Methoxy-6-methyl-phenyl)-3-{3-[8-(pyridin-4-ylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

91. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(2-Methoxy-5-methyl-phenyl)-3-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-urea.

92. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-{3-[8-(3-Chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(2-methoxy-5-methyl-phenyl)-urea.

93. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-{3-[8-(2-Chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(2-methoxy-5-methyl-phenyl)-urea.

94. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-{3-[8-(Pyridin-3-ylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-trifluoromethyl-phenyl)-urea.

95. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug therof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-{3-[8-(pyridin-3-ylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

96. A compound or salt according to claims 1 to 95, wherein in an in vitro assay of kinase modulation, the compound exhibits a IC_{50} value less than or equal to 25 micromolar.

97. A pharmaceutical composition comprising a compound or salt according to claims 1 to 95, combined with at least one pharmaceutically acceptable carrier or excipient.

98. A method of treating a kinase-implicated condition in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound or salt of claims 1 to 95.

99. The method of claim 98, wherein the mammal is a human.

100. The method of claim 98, wherein the mammal is a dog or cat.

101. A method for identifying a kinase, comprising contacting an organism, cell, or preparation comprising the kinase with compound or salt according to claim 1, and detecting modulation of an activity of the kinase.